Stay updated with breaking news from Ajay Nooka. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Pfizer Inc. (NYSE:PFE) today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval to ELREXFIO™ (elranatamab-bcmm) for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have recei
The FDA has granted accelerated approval to elranatamab-bcmm (Elrexfio) for the treatment of adult patients with relapsed or refractory multiple myeloma who have previously received at least 4 lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
Elranatamab-bcmm (Elrexfio; Pfizer) is a BCMA-CD3-targeted bispecific antibody approved for adults with relapsed or refractory multiple myeloma who were previously administered at least 4 lines of therapy that included a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
Elranatamab produced 58% response rate as fifth-line therapy
The approval of ELREXFIO is based on clinically meaningful response rates and duration of response from Phase 2 MagnetisMM-3 study ELREXFIO is the first off-the-shelf fixed-dose subcutaneous... -Today at 02:09 pm- MarketScreener